Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.

Manju Dawkins, MD, discusses Skin Angels, why clinicians belong in dermatology innovation, and her work to reduce injection pain and needle anxiety.

Discover how newly cleared weekly basal insulin efsitora reshapes type 2 diabetes care—QWINT results, hypoglycemia edge, and dosing tips.

FDA clears Eli Lilly’s Onswik weekly insulin from QWINT trials, cutting injections for type 2 diabetes while matching daily basal control.

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.